Fundraising Fox
Interface Biosciences
Founded 2020 · 2 employees on LinkedIn · 5 known investors
Find your way into Interface Biosciences
Sign up to see every warm intro you have to Interface Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Interface Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Interface Bio develops immunotherapies targeting complex inflammatory diseases by combining biological evolution, metabolomics, and machine learning to discover natural-derived therapeutic products.
Investors · 5
__Twitter.png)
One Planet Grouplisted by One Planet GroupSan Francisco
How we know: One Planet Group's portfolio page · Not right? Tell us
StartXlisted by StartXStanford · $10K – $1M
How we know: StartX's portfolio page · Not right? Tell us
Ulu Ventureslisted by Ulu VenturesPalo Alto · $2M
How we know: Ulu Ventures's portfolio page · Not right? Tell us
Pear VCreportedSan Francisco · $150K – $4M
How we know: funding news · Not right? Tell us
Related companies · 8
Transition BioTransition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
ARTBIOARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue. The company covers the design, manufacture, and distribution of its therapies and builds on radiation research from the University of Oslo and Norway's Radium Hospital.
Integrated BiosciencesIntegrated Biosciences is a biotech company developing treatments and interventions for aging-related diseases using a combination of medicinal chemistry, biochemistry, aging biology, and artificial intelligence.
Form BioForm Bio develops AI-driven software and bioinformatics tools for genetic medicine and genome engineering, enabling faster and safer design of gene therapies, protein engineering, and manufacturing optimization.
Emulate BioEmulate builds Organ-on-a-Chip systems, including platforms, consumables, and pre-assembled BioKits with validated human cell models, to support drug discovery research. It serves life sciences and pharmaceutical researchers and provides installation, training, and validated protocols for Organ-Chip experiments.
Formation BioFormation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Assembly BiosciencesAssembly Bio is a biopharmaceutical company developing novel therapeutic candidates for viral and liver diseases, including programs targeting herpesviruses, hepatitis delta virus, hepatitis B virus, and cholestatic liver diseases.
Companies working in the same space as Interface Biosciences.
Frequently asked questions
- What does Interface Biosciences do?
- Interface Bio develops immunotherapies targeting complex inflammatory diseases by combining biological evolution, metabolomics, and machine learning to discover natural-derived therapeutic products.
- Who are Interface Biosciences's investors?
- Interface Biosciences's investors include Gaingels, One Planet Group, StartX, Ulu Ventures, Pear VC.